Reuters logo
BRIEF-NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer
September 25, 2017 / 10:36 AM / 3 months ago

BRIEF-NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

Sept 25 (Reuters) - Newlink Genetics Corp

* NewLink Genetics announces clinical collaboration to evaluate IO-based combination therapies in pancreatic cancer

* Phase 2 trial will be funded equally by both companies, with NewLink Genetics serving as study sponsor Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below